title: NMDA receptor antagonists change behavioral activity of rats treated with (S)-4CPG.
abstract: The effect of (S)-4CPG [(S)-4-carboxyphenylglycine] (25, 50, 100 nmol icv) and the effect of AP-7 (5 nmol icv) or MK-801 (5 nmol icv) on the processes of acquisition, consolidation of conditioned reflexes and locomotor activity were tested in rats. Neither AP-7, MK-801 nor (S)-4CPG given alone changed locomotor activity. MK-801 significantly increased the effects of (S)-4CPG: on crossings at all applied doses, on rearings at 100 nmol, and on bar approaches at 50 nmol of (S)-4CPG. AP-7 enhanced the effects of 50 and 100 nmols of (S)-4CPG on crossings, 100 nmol of (S)-4CPG on rearings in the open field test. Neither AP-7, MK-801 nor (S)-4CPG at doses of 50 and 100 nmols influenced acquisition, but (S)-4CPG given alone at a dose of 25 nmol impaired acquisition. MK-801 impaired the action of 50 and 100 nmols of (S)-4CPG on acquisition. AP-7 only at a dose of 100 nmol inhibited (S)-4CPG-induced acquisition. Neither AP-7, MK-801 nor (S)-4CPG given alone changed consolidation in passive avoidance situation while co-administration of AP-7 and (S)-4CPG at the doses of 50 and 100 nmols, affected this process. The obtained results support our hypothesis concerning the co-operation between group I mGluRs and NMDA receptors in some behavioral tests and the modulating effect of group I mGluRs antagonist on central action of NMDA receptor antagonists.
authors: Department of Pharmacology, Medical Academy, Białystok, Poland.
authors: H
authors: H
authors: Car
authors: R
authors: R
authors: Oksztel
authors: A
authors: A
authors: Nadlewska
authors: K
authors: K
authors: Wiśniewski
mesh_terms: D015763:2-Amino-5-phosphonovalerate / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D001362:Avoidance Learning / Q000187:drug effects; D001522:Behavior, Animal / Q000187:drug effects*; D001565:Benzoates / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D001667:Binding, Competitive; D016291:Dizocilpine Maleate / Q000008:administration & dosage / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D005106:Exploratory Behavior / Q000187:drug effects; D005998:Glycine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology*; D007276:Injections, Intraventricular; D017774:Long-Term Potentiation / Q000187:drug effects; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D018094:Receptors, Metabotropic Glutamate / Q000037:antagonists & inhibitors; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*; D013237:Stereoisomerism
chemical_list: D001565:Benzoates; D018691:Excitatory Amino Acid Antagonists; D018094:Receptors, Metabotropic Glutamate; D016194:Receptors, N-Methyl-D-Aspartate; C104077:metabotropic glutamate receptor type 1; D016291:Dizocilpine Maleate; C079693:4-carboxyphenylglycine; D015763:2-Amino-5-phosphonovalerate; C031231:2-amino-7-phosphonoheptanoic acid; D005998:Glycine